http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#Head
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#provenance
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#pubinfo
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion
http://purl.obolibrary.org/obo/DOID_8567
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8567
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00262
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
http://www.w3.org/2000/01/rdf-schema#label
carmustine for injection usp is indicated as palliative therapy as a single agent or in established combination therapy in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors multiple myeloma in combination with prednisone relapsed or refractory hodgkin s lymphoma in combination with other approved drugs relapsed or refractory non hodgkin s lymphomas in combination with other approved drugs carmustine for injection usp is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors 1 multiple myeloma in combination with prednisone 1 relapsed or refractory hodgkin s lymphoma in combination with other approved drugs 1 relapsed or refractory non hodgkin s lymphomas in combination with other approved drugs 1
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00262
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#provenance
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#pubinfo
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig
http://purl.org/nanopub/x/hasSignature
FF/pUWp+bo3IA0XV6oV5uPiP3kVLfWQ9GBsKPDYvwlFnlwJDcjp/eEHUOwpCHka6ndQkf3/coSgFUUg4YuUtV/ckYI3tXy1baggJB1yCjoGbzNWgRui71MpWYbkg0+x07ro/wzRGDnDtTpCt1I4ypM+wPDrRNjYuKZjeSlL3CGk=
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://purl.org/dc/terms/created
2021-06-28T08:06:40.117+02:00
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs